Cargando…
Progress in Adenoviral Capsid-Display Vaccines
Adenoviral vectored vaccines against infectious diseases are currently in clinical trials due to their capacity to induce potent antigen-specific B- and T-cell immune responses. Heterologous prime-boost vaccination with adenoviral vector and, for example, adjuvanted protein-based vaccines can furthe...
Autores principales: | Vujadinovic, Marija, Vellinga, Jort |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165093/ https://www.ncbi.nlm.nih.gov/pubmed/30049954 http://dx.doi.org/10.3390/biomedicines6030081 |
Ejemplares similares
-
Antigen capsid-display on human adenovirus 35 via pIX fusion is a potent vaccine platform
por: Salisch, Nadine C., et al.
Publicado: (2017) -
Capsid and Genome Modification Strategies to Reduce the Immunogenicity of Adenoviral Vectors
por: Kreppel, Florian, et al.
Publicado: (2021) -
Multivalent adenoviral vectors which use an antigen capsid-incorporation strategy for HIV vaccination
por: Gu, L, et al.
Publicado: (2012) -
Transcriptional Activation of the Adenoviral Genome Is Mediated by
Capsid Protein VI
por: Schreiner, Sabrina, et al.
Publicado: (2012) -
Advantages and Prospects of Tag/Catcher Mediated Antigen Display on Capsid-Like Particle-Based Vaccines
por: Aves, Kara-Lee, et al.
Publicado: (2020)